Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. - Wikidata - awgldk - TriplyDB

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

http://www.wikidata.org/entity/Q43886356

about

Erythropoiesis-stimulating agents for myelodysplastic syndromes Subcutaneous versus intravenous erythropoietin for long-term dialysis patients Subcutaneous versus intravenous erythropoietin for long-term dialysis patients Erythropoiesis-stimulating agents for myelodysplastic syndromes Erythropoietin for patients with malignant disease Erythropoietin or Darbepoetin for patients with cancer Treatment for women with postpartum iron deficiency anaemia Immunogenicity of protein therapeutics: The key causes, consequences and challenges Acquired pure red cell aplasia: updated review of treatment Role of iron in anaemic critically ill patients: it's time to investigate!Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Assessing the Immunogenicity of Biopharmaceuticals Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes The emergence of biosimilar insulin preparations--a cause for concern?Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach Recent advances in sialic acid-focused glycomics Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy Erythropoietin: a candidate compound for neuroprotection in schizophrenia Characterizing biological products and assessing comparability following manufacturing changes.Comparative testing and pharmacovigilance of biosimilars.Pharmacy and pharmacology of biosimilars.Clinical considerations for biosimilar antibodies.Drug-induced hematologic syndromes Immunogenicity and other problems associated with the use of biopharmaceuticals.Blood disorders typically associated with renal transplantation Safety, Tolerability, and Immunogenicity of Interferons Current methods for detecting antibodies against erythropoietin and other recombinant proteins.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies Anti-cytokine autoantibodies explain some chronic mucocutaneous candidiasis.Prevention of siderophore- mediated gut-derived sepsis due to P. aeruginosa can be achieved without iron provision by maintaining local phosphate abundance: role of pH.Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades.Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats Trophic factors and stem cells for promoting recovery in stroke.Immunogenicity to biologics: mechanisms, prediction and reduction.

P2860

Q24186244-0FF35A5C-A731-499F-943C-43E2DD5CA3BB Q24187032-C7E4ADB1-E775-4F11-B908-7C3BDB84C898 Q24200417-C9CF3477-2B12-4CBE-A6E8-E876FA9A0F24 Q24202526-565A63AE-62BA-42E1-A662-2A96BD100CD2 Q24245427-118132F9-D238-4BE6-AC28-AE48BF2EF07D Q24245464-5222261A-4699-4D6D-AE03-909ADAF7983F Q24246075-58C25FE7-F58C-45F1-8C51-FCF2F056CBBA Q24633296-FAA60987-FC47-4605-8B27-438D96F7EBD4 Q24652253-FAFBF673-992A-4A91-8E68-092A0509613F Q24799718-CBF472B0-D201-45C1-B0CA-19D7D9985144 Q26738810-A360FAB7-6EFB-489B-B649-A7385F4005F7 Q26751485-505AF971-C3C7-401B-A579-51FAC3493572 Q26766424-C0616774-100C-4201-B2D8-0C84FF5C86B0 Q26824362-D67431F7-8337-46EB-8B17-217D353AF1D1 Q26865481-73E8EEA0-0707-4592-A2F8-E5A118E58F85 Q26866630-C7518A06-183D-4ABE-86D8-C94D50889635 Q27009385-C346E770-8005-470A-93D8-1268E73E7955 Q28066377-A669A0B8-B321-42BD-9C53-5478BE003D2F Q28212816-02E7E83E-C8B3-419A-A2C8-80425893B592 Q30344134-879E8B9A-2FC2-4CFE-B130-970D043ADC65 Q30356696-5DFC15FE-1B9E-42AA-B8E1-E4046F9F0245 Q30370042-1F5B5176-A5A6-40FC-93C3-6ABE7B88D9C8 Q30377239-C10CEE14-9B50-4E4C-BB5E-24199181C1F0 Q33387312-53F47672-CE69-444E-8A2A-57A76A9A5A95 Q33416851-C7D94E14-BB4E-477A-B26A-999D0800A324 Q33421793-35410E9D-10D8-4D2C-8F40-64D798CB7BAC Q33435810-D3826E52-E7F9-4F1E-B138-3B4ABC51F2FE Q33593537-12E74A34-98D6-46B4-83E8-9CB4907F4069 Q33652098-CDC86173-6FC7-4422-9D6B-4D234F9EF4A4 Q33685447-72A1A350-A4A3-432E-8567-9148A3F14367 Q33745965-A97AC715-7721-412E-A96C-0B4E5A81A2EB Q33804009-DC221C81-6065-4D0B-8D05-39FECED72689 Q33895804-5BE0B46A-0E56-4FB1-951C-901D75CD9ED3 Q33921744-0D19F442-8841-436E-BBE3-6E15F0DCD1D1 Q34029032-81EBEF16-8809-4242-BE07-C8D985D9FD70 Q34064079-0F98E439-55AB-45A4-8512-36C74BADB051 Q34125272-DE40AD93-5F77-428A-BE0C-1D75647F4CFE Q34128875-BFE6E595-50CF-4578-9828-D5B4BDFB764D Q34240109-58039A2F-0C2F-4215-8529-888D5E6662F3 Q34296526-155046E0-2BC6-4913-A453-06964A55F85F

P2860

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

http://www.wikidata.org/entity/Q43886356

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@en

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@nl

type

label

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@en

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@nl

prefLabel

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@en

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@nl

P1433

Q43886356-6FD2BE21-C655-4CEC-B5DA-B9292A5AB7BA

P1476

Q43886356-9A6CA133-8A43-4E2A-87B7-841922E217F1

P2093

Q43886356-07024217-FFE9-4F0A-8DCD-FE026BBEF404

Q43886356-104D8A1D-2362-4F6B-93F9-C3ED676728D3

Q43886356-24CE397B-EE76-4C34-8ABE-CBA71D915ACB

Q43886356-2D7AC3C6-DFEC-4CB9-B3CC-3392E18982E1

Q43886356-422190D7-CC7D-46E3-94AF-3861A22F27A3

Q43886356-7CA41478-1137-4AC9-AA20-2D796E044986

Q43886356-95FA93E4-6F43-4789-9165-2C9932F62786

Q43886356-A9F4328C-2349-4D67-A7F4-9E9B84F9C0B7

Q43886356-B1B71E88-E332-410F-98D3-2A583E72E1B6

Q43886356-D2F98BCC-10E9-4BCF-93F6-930C05331430

P304

Q43886356-BE27E9E6-6AB5-4D96-89AD-DF3D99DD232A

P31

Q43886356-CDD2DFA6-4D29-4A7B-8904-BA852EFFBA0D

P356

Q43886356-C7751329-14B8-4281-BFB2-BF6E6A3CD2F3

P407

Q43886356-3C0C0D65-247F-4494-8529-BA6396334272

P433

Q43886356-10C2FB17-80A2-416C-B525-E76BA056F566

P478

Q43886356-546E55C7-A62F-4086-8136-DE38DCE70B7D

P50

Q43886356-724FE294-37C0-4342-B8DA-70F3C588516E

P577

Q43886356-5C8B44FE-DAA8-4A73-905E-54C9991A4855

P5875

Q43886356-81A00F2F-EB49-4A88-A51D-B29D27ED0BB4

P698

Q43886356-203F5F06-98A5-4714-A549-919C3009D813

P921

Q43886356-34CAC4F2-02A9-4283-BB28-141F84049A90

Q43886356-997CFA27-982E-406D-8292-5515ED8D94B8

P356

P1433

The New England Journal of Medicine

P1476

Pure red-cell aplasia and anti ...... th recombinant erythropoietin.

@en

P2093

Amir Kolta

http://www.w3.org/2001/XMLSchema#string

Beatrice Viron

http://www.w3.org/2001/XMLSchema#string

Bruno Varet

http://www.w3.org/2001/XMLSchema#string

Irene Teyssandier

http://www.w3.org/2001/XMLSchema#string

Joelle Nataf

http://www.w3.org/2001/XMLSchema#string

Nicole Casadevall

http://www.w3.org/2001/XMLSchema#string

Patrick Mayeux

http://www.w3.org/2001/XMLSchema#string

Patrick Michaud

http://www.w3.org/2001/XMLSchema#string

Philippe Martin-Dupont

http://www.w3.org/2001/XMLSchema#string

Thomas Papo

http://www.w3.org/2001/XMLSchema#string

P304

469-475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA011931

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Jacques Kiladjian

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11516107

http://www.w3.org/2001/XMLSchema#string

P698

11844847

http://www.w3.org/2001/XMLSchema#string

P921